
Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:



- 15. (Cancelled).
- 16. (Cancelled).
- 17. (Cancelled).
- 18. (Cancelled).
- 19. (Cancelled).
- 20. (Cancelled).
- 21. (Cancelled).
- 22. (Cancelled).
- 23. (Cancelled).
- 24. (Cancelled).
- 25. (Cancelled).
- 26. (Cancelled).
- 27. (Cancelled).
- 28. (Cancelled).
- 29. (Cancelled).
- 30. (Currently Amended) A mutant antibody that comprises a mutant immunoglobulin chain, the mutant antibody having higher affinity for an antigen than a parent antibody that comprises a parent immunoglobulin chain, wherein the mutant immunoglobulin chain comprises an amino acid substitution that eliminates a variable region glycosylation site of

the parent immunoglobulin chain, said elimination having the effect of increasing the affinity of the mutant antibody relative to the parent antibody.

- 31. (Previously Presented) The mutant antibody of claim 30, wherein the glycosylation site is an N-linked glycosylation site selected from the group consisting of:
 - (1) -Asn-X-Ser-; and
 - (2) -Asn-X-Thr-;

wherein X is an amino acid other than Pro.

- 32. (Currently Amended) The mutant antibody of claim 30, wherein the glycosylation site is an 0-linked glycosylation site selected from the group consisting of:
 - (1) -Thr-X-X-Pro-; and
 - (2) —Ser-X-Y-Pro-;

wherein X is an amino acid.

- 33. (Currently Amended) The mutant antibody of claim 30, wherein the mutant antibody is a humanized version of the parent antibody.
- 34. (Currently Amended) The mutant antibody of claim 30, whose variable region has no glycosylation sites.
- 35. (Currently Amended) The mutant antibody of claim 30, whose variable region has no N-linked glycosylation sites.
- 36. (Currently Amended) The mutant antibody of claim 30, wherein the parent antibody is murine M195 antibody.
- 37. (Currently Amended) The mutant antibody of claim 30, wherein the mutant antibody is a humanized M195 antibody.
- 38. (Currently Amended) The mutant antibody of claim 30, wherein the antigen is a cell surface glycoprotein.

- 39. (Currently Amended) The mutant antibody of claim 30, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.
- 40. (Currently Amended) The mutant antibody of claim 30, wherein the amino acid substitution is a conservative amino acid substitution.
- 41. (Currently Amended) The mutant antibody of claim 31, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.
- 42. (Currently Amended) The mutant antibody of claim 31, wherein the amino acid substitution is a conservative amino acid substitution.
- 43. (Currently Amended) The mutant antibody of claim 32, wherein the mutant immunoglobulin chain is an immunoglobulin heavy chain.
- 44. (Currently Amended) The mutant antibody of claim 32, wherein the amino acid substitution is a conservative amino acid substitution.
- 45. (Currently Amended) The mutant antibody of claim 38, wherein the cell surface glycoprotein is the CD33 antigen.